ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 817

Circulating Endothelial Cell (CEC) and CEC-Bound C4d Levels As Biomarkers of Systemic Lupus Erythematosus

Chau-Ching Liu1, Susan Manzi2 and Joseph Ahearn3, 1Allegheny Singer Research Institute, Pittsburgh, PA, 2Rheumatology, Allegheny Health Network, Pittsburgh, PA, 3Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: biomarkers and complement, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Accelerated atherosclerotic disease has been widely recognized in patients with SLE. Circulating endothelial cells (CECs) are a rare cell population believed to detach from the vessel wall as a result of vascular injury. Increased numbers of CECs have been reported previously in patients with SLE. However, the interaction between complement and CECs with regard to inflammatory vascular injury in SLE has not been explored. Previous studies have shown that complement activation product C4d is present specifically on platelets of SLE patients and correlates with cerebrovascular disease. These observations led us to hypothesize that increased numbers of CECs bearing C4d may serve as a sensitive and specific biomarker of SLE-associated vascular diseases.

Methods:

To verify this hypothesis, a pilot study investigating CEC numbers and CEC-bound C4d levels was conducted using the blood samples taken from 129 patients with SLE, 125 patients with other immune-inflammatory diseases, and 30 healthy individuals. Peripheral blood mononuclear cells were isolated, and CECs therein were detected and analyzed for surface-bound C4d by flow cytometry.

Results:

Preliminary results showed that CEC numbers per se were not significantly elevated in patients with SLE. Notably, however, the levels of CEC bearing C4d (CEC-C4d) were significantly elevated in patients with SLE (specific median fluorescence intensity (SMFI) = 16.7), compared to patients with other diseases (SMFI = 5.7; p <0.001) and healthy controls (SMFI = 3.5; p <0.001). In a preliminary cross-sectional analysis, CEC-C4d measure was 45% sensitive and 100% specific for SLE versus healthy controls, and 86% specific for SLE versus other diseases. Furthermore, there was a correlation between CEC-C4d and platelet-bound C4d levels (Spearman r = 0.40, p <0.001). Because platelets play important roles in hemostasis and thrombosis and have increasingly been recognized as being important mediators of inflammation, this finding suggests an interactive participation of platelets and CECs in SLE-associated inflammatory vascular disease.

Conclusion:

The results obtained indicate that CEC-C4d is a potential diagnostic marker of SLE and possibly a stratification biomarker for vasculature-specific SLE disease activity.


Disclosure: C. C. Liu, Exagen Dgnostics, 7; S. Manzi, Exagen Dagnostics, 7; J. Ahearn, Exagen Diagnostics, 7.

To cite this abstract in AMA style:

Liu CC, Manzi S, Ahearn J. Circulating Endothelial Cell (CEC) and CEC-Bound C4d Levels As Biomarkers of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/circulating-endothelial-cell-cec-and-cec-bound-c4d-levels-as-biomarkers-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-endothelial-cell-cec-and-cec-bound-c4d-levels-as-biomarkers-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology